IRF2BP1

Across TCGA pan-cancer cohorts, IRF2BP1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of IRF2BP1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where IRF2BP1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IRF2BP1 is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

LIHC, COAD, and KICH are the cancer types where IRF2BP1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IRF2BP1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+0.873	<.001	9	view →
COAD	Female	All	+0.567	<.001	9	view →
KICH	All	All	−0.631	<.001	7	view →
HNSC	All	All	+0.307	.009	6	view →
LUSC	All	All	+0.487	<.001	5	view →
THCA	Male	IV	−0.813	.020	4	view →
STAD	All	All	+0.528	.004	4	view →
ESCA	All	All	+0.483	.018	4	view →
CHOL	All	All	+0.817	.001	2	view →
BRCA	All	III,IV	+0.445	.019	2	view →
UCEC	All	II,III,IV	−0.377	.020	2	view →
PAAD	All	All	+0.317	.038	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

IRF2BP1–LIHC

Open the LIHC breakdown →